USE OF REDD1 INHIBITORS TO DISSOCIATE THERAPEUTIC AND ADVERSE ATROPHOGENIC EFFECTS OF GLUCOCORTICOID RECEPTOR AGONISTS

摘要

Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and administering to the patient in need thereof a REDD1 inhibitor that inhibits expression or activity of REDD1, wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.

主权项

1. A method comprising administering to a patient in need thereof a glucocorticoid receptor (GR) agonist and an inhibitor of regulated in development and DNA damage response protein 1 (REDD1 inhibitor), wherein the REDD1 inhibitor is administered before, concurrently with, or after the GR agonist is administered.